A citation-based method for searching scientific literature

Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee-Chen Chang, Lucio Crino, Miyako Satouchi, Quincy Chu, Toyoaki Hida, Ji-Youn Han, Oscar Juan, Frank Dunphy, Makoto Nishio, Jin-Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi. Lancet Oncol 2016
Times Cited: 368



Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen, Chee K Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A Papadimitrakopoulou. N Engl J Med 2017
Times Cited: 1526




List of shared articles



Times cited

Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Kazuhiko Nakagawa, Koichi Matsumura, Tayler Scory, Megan S Farris, Kelly A Larkin-Kaiser, Hironori Kikkawa, Jasmina I Ivanova, Keith D Wilner. Future Oncol 2021
0


Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Helena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R Wijayawardana,[...]. Clin Cancer Res 2021
9


Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter, Cosmin Sebastian Voican. Crit Rev Oncol Hematol 2021
1

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
Misako Nagasaka, Viola W Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
5

Cardiac Safety of Osimertinib: A Review of Data.
Michael S Ewer, Sri Harsha Tekumalla, Andrew Walding, Kwame N Atuah. J Clin Oncol 2021
7

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel. Int J Mol Sci 2021
3

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Da Peng, Dongfeng Shan, Chengcheng Dai, Jie Li, Zifan Wang, Ziyi Huang, Rui Peng, Peng Zhao, Xuezhen Ma. Cancer Manag Res 2021
2

EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.
Reina Hara, Masaki Kanazu, Ami Iwai, Tomoki Kuge, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori. Thorac Cancer 2021
1

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Yulong Fu, Anqi Wang, Jieqi Zhou, Wei Feng, Minhua Shi, Xiao Xu, Hongqing Zhao, Liming Cai, Jian Feng, Xuedong Lv,[...]. Front Oncol 2021
1

Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
Wenqian Li, Lei Qian, Wei Li, Xiao Chen, Hua He, Huimin Tian, Yuguang Zhao, Xu Wang, Jiuwei Cui. Exp Ther Med 2021
0


Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis.
Chunsheng Wang, Kewei Zhao, Shanliang Hu, Minghuan Li, Yipeng Song. Front Oncol 2021
2

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Anna Buder, Ellen Heitzer, Julie Waldispühl-Geigl, Sabrina Weber, Tina Moser, Maximilian J Hochmair, Klaus Hackner, Peter Errhalt, Ulrike Setinek, Martin Filipits. Biomolecules 2021
2

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Luwei Han, Xiaomeng Zhang, Zhiqiang Wang, Xian Zhang, Liwen Zhao, Wei Fu, Xiaobo Liang, Zhibo Zhang, Yong Wang. Front Pharmacol 2021
0

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Kejun Liu, Xianwen Chen, Ligang Wu, Shiyuan Chen, Nianxin Fang, Limin Cai, Jun Jia. BMC Pulm Med 2021
1

0

Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature.
M Zeeshan Ozair, Alexandra M Giantini Larsen, Juliana Eng, Nelson S Moss. JCO Precis Oncol 2021
0

Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review.
Elisabeth Smolle, Valentin Taucher, Jörg Lindenmann, Martin Pichler, Freyja-Maria Smolle-Juettner. Transl Lung Cancer Res 2021
1


Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Mariona Riudavets, Joaquim Bosch-Barrera, Luís Cabezón-Gutiérrez, Pilar Diz Taín, Ainhoa Hernández, Miriam Alonso, Remei Blanco, Elisa Gálvez, Amelia Insa, Xabier Mielgo,[...]. Clin Transl Oncol 2021
1



Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report.
Yozo Sato, Akimasa Sekine, Eri Hagiwara, Midori Sato, Takafumi Yamaya, Masato Asaoka, Katsuyuki Higa, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu,[...]. Respir Med Case Rep 2021
0

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari,[...]. Oncologist 2021
0

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma.
Caterina Gianni, Giuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, Kalliopi Andrikou, Manlio Monti, Cecilia Menna, Giovanni Luca Frassineti, Lucio Crinò. Front Pharmacol 2021
0

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
Xin Tang, Yuan Li, Wen-Lei Qian, Wei-Feng Yan, Tong Pang, You-Ling Gong, Zhi-Gang Yang. J Cancer Res Clin Oncol 2021
0

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Atsushi Osoegawa, Masafumi Yamaguchi, Tomomi Nakamura, Ryotaro Morinaga, Kentaro Tanaka, Kosuke Kashiwabara, Takashi Miura, Takayuki Suetsugu, Taishi Harada, Tatsuma Asoh,[...]. JTO Clin Res Rep 2021
0

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
0

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Takahisa Kawamura, Hirotsugu Kenmotsu, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori,[...]. Invest New Drugs 2020
2

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee. Cancer Res Treat 2020
1

Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report.
Atsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, Kei Irie, Shoji Fukushima, Keisuke Tomii. Invest New Drugs 2020
2

Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
Karthick Vishwanathan, Mireille Cantarini, Karen So, Eric Masson, Jennifer Fetterolf, Suresh S Ramalingam, R Donald Harvey. Clin Transl Sci 2020
1

Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis.
Z-X Li, W Zhao, Q Sun, M-S Tang, Q-J Xia, M-S Dong. Clin Transl Oncol 2020
1

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.
Byoung Chul Cho, Dong-Wan Kim, Keunchil Park, Jong-Seok Lee, Seung Soo Yoo, Jin Hyoung Kang, Sung Yong Lee, Cheol Hyeon Kim, Seung Hun Jang, Young-Chul Kim,[...]. Curr Med Res Opin 2020
2

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Valentina Polo, Fabiana Letizia Cecere, Alessandro Del Conte, Giorgia Nardo, Vanessa Buoro,[...]. Clin Lung Cancer 2020
11

Genomics and the History of Precision Oncology.
Deborah B Doroshow, James H Doroshow. Surg Oncol Clin N Am 2020
5

Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Daniel Moldaver, Manjusha Hurry, William K Evans, Parneet K Cheema, Randeep Sangha, Ronald Burkes, Barbara Melosky, Diana Tran, Darryl Boehm, Jaya Venkatesh,[...]. Lung Cancer 2020
6

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong-Mu Sun,[...]. J Clin Oncol 2020
80

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Maria Lucia Reale, Rita Chiari, Marcello Tiseo, Fabiana Vitiello, Fausto Barbieri, Diego Cortinovis, Giovanni Luca Ceresoli, Giovanna Finocchiaro, Gianpiero Diego Romano, Pier Luigi Piovano,[...]. Lung Cancer 2020
1

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
Myung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, Ji-Youn Han, Sarah B Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin Johnson,[...]. J Thorac Oncol 2020
22

Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials.
Bishal Gyawali, Elvira D'Andrea, Jessica M Franklin, Aaron S Kesselheim. J Natl Compr Canc Netw 2020
10

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu,[...]. Clin Cancer Res 2020
17

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Yuankai Shi, Shucai Zhang, Xingsheng Hu, Jifeng Feng, Zhiyong Ma, Jianying Zhou, Nong Yang, Lin Wu, Wangjun Liao, Dafang Zhong,[...]. J Thorac Oncol 2020
14

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients.
Qiufan Zheng, Shaodong Hong, Yan Huang, Hongyun Zhao, Yunpeng Yang, Xue Hou, Yuanyuan Zhao, Yuxiang Ma, Ting Zhou, Yaxiong Zhang,[...]. Clin Transl Med 2020
8

Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Wen Ouyang, Jing Yu, Zhao Huang, Gang Chen, Yu Liu, Zhengkai Liao, Wei Zeng, Junhong Zhang, Conghua Xie. J Cancer 2020
3

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Takayuki Kishikawa, Takashi Kasai, Masahiko Okada, Ichiro Nakachi, Sayo Soda, Ryo Arai, Ayako Takigami, Masafumi Sata. Thorac Cancer 2020
6


Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Chennianci Zhu, Weihao Zhuang, Limin Chen, Wenyu Yang, Wen-Bin Ou. Transl Lung Cancer Res 2020
7